Neuroprotective effect of lovastatin by inhibiting NMDA receptor1 in 6-hydroxydopamine treated PC12 cells

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 10, 2014, Pages 3313-3319

  Yan, Junqiang ^a   Ma, Yu Jin ^a   Sun, Jia Chun ^a   Bai, Shu Feng ^a   Huang, Li Na ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Lovastatin; NMDA receptor1; Parkinson s disease; TNF

Indexed keywords

LACTATE DEHYDROGENASE; MESSENGER RNA; MEVINOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; OXIDOPAMINE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MTT ASSAY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84910079969     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Undela K, Gudala K, Malla S and Bansal D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 2013; 260: 158-165.
2. Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH and Lai MS. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013; 81: 410-416.
3. Janssen WG, Vissavajjhala P, Andrews G, Moran T, Hof PR and Morrison JH. Cellular and synaptic distribution of NR2A and NR2B in macaque monkey and rat hippocampus as visualized with subunit-specific monoclonal antibodies. Exp Neurol 2005; 191 Suppl 1: S28-44.
4. Nilsson A, Eriksson M, Muly EC, Akesson E, Samuelsson EB, Bogdanovic N, Benedikz E and Sundstrom E. Analysis of NR3A receptor subunits in human native NMDA receptors. Brain Res 2007; 1186: 102-112.
5. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis 2004; 15: 80-92.
6. Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci 2006; 26: 4690-4700.
7. Hallett PJ and Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004; 102: 155-174.
8. Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 2006; 69: 805-812.
9. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 2005; 196: 422-429.
10. Rodriguez-Blanco J, Martín V, Herrera F, García-Santos G, Antolín I, Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 2008; 107: 127-140.
11. Yeh SH, Hung JJ, Gean PW, Chang WC. Hypoxia-inducible factor-1alpha protects cultured cortical neurons from lipopolysaccharide-induced cell death via regulation of NR1 expression. J Neurosci 2008; 28: 14259-14270.
12. Galic MA, Riazi K, Henderson AK, Tsutsui S, Pittman QJ. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009; 36: 343-351.
13. Sasaki J, Kofuji S, Itoh R, Momiyama T, Takayama K, Murakami H, Chida S, Tsuya Y, Takasuga S, Eguchi S, Asanuma K, Horie Y, Miura K, Davies EM, Mitchell C, Yamazaki M, Hirai H, Takenawa T, Suzuki A, Sasaki T. The PtdIns(3,4)P(2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death. Nature 2010; 465: 497-501.
14. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 2010; 30: 11246-11250.
15. Betzen C, White R, Zehendner CM, Pietrowski E, Bender B, Luhmann HJ, Kuhlmann CR. Oxidative stress upregulates the NMDA receptor on cerebrovascular endothelium. Free Radic Biol Med 2009; 47: 1212-1220.
16. Wang C, Sadovova N, Hotchkiss C, Fu X, Scallet AC, Patterson TA, Hanig J, Paule MG, Slikker W Jr. Blockade of N-methyl-D-aspartate receptors by ketamine produces loss of postnatal day 3 monkey frontal cortical neurons in culture. Toxicol Sci 2006; 91: 192-201.
17. Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W and Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental par kinsonian models: the association with anti-inflammatory responses. PLoS One 2011; 6: e20945.
18. Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 2009; 29: 6007-6012.
19. Lebrun-Julien F, Duplan L, Pernet V, Osswald I, Sapieha P, Bourgeois P, Dickson K, Bowie D, Barker PA, Di Polo A. Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci 2009; 29: 5536-5545.
20. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, Mattson MP, Geiger JD, Haughey NJ. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem 2009; 109: 1237-1249.